Bringing diagnostic technologies to the clinical laboratory: Rigor, regulation, and reality

Proteomics - Clinical Applications

Volumn 2, Issue 10-11, 2008, Pages 1378-1385

  Whiteley, Gordon ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Biomarker development; FDA filing

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; OSTEOPONTIN; PROLACTIN;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; EXPERIMENTAL DESIGN; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; MASS SPECTROMETRY; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS TECHNOLOGY; PROTEIN MICROARRAY; REPRODUCIBILITY; REVIEW; SAFETY; SENSITIVITY AND SPECIFICITY;

EID: 64649094843     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780170     Document Type: Review

References (36)

1. Check, E., Proteomics and cancer: Running before we can walk? Nature 2004, 429, 496-497.
2. Geraghty, J., Adenomatous polyposis coli and translational medicine. Lancet 1996, 348, 422.
3. Crist, T. B., Schafer, A. I., Walsh, R. A., Translating basic discoveries into better health care: The APM's recommendations for improving translational research. Am. J. Med. 2004, 116, 431-434.
4. Lawrence, P. A., The mismeasurement of science. Curr. Biol. 2007, 17, R583-R585.
5. Kim, J. H., Skates, S. J., Uede, T., Wong, K. K. et al., Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287, 1671-1679.
6. Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F. et al., Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers. Prev. 2005, 14, 981-987.
7. Mor, G., Visintin, I., Lai, Y., Zhao, H. et al., Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 7677-7682.
8. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
9. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
10. Krouwer, J. S., Assay Development and Evaluation - A Manufacturer's Perspective, AACC Press, Washington, DC 2002.
11. Phillips, K. A., Van Bebber, S., Issa, A. M., Diagnostics and biomarker development: Priming the pipeline. Nat. Rev. Drug Discov. 2006, 5, 463-469.
12. Lim, M., Ye, H., Panoskaltsis, N., Drakakis, E. M. et al., Intelligent bioprocessing for haemotopoietic cell cultures using monitoring and design of experiments. Biotechnol. Adv. 2007, 25, 353-368.
13. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359, 572-577.
14. Petricoin, E. F., III, Ornstein, D. K., Paweletz, C. P., Ardekani, A. et al., Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 2002, 94, 1576-1578.
15. Kozak, K. R., Amneus, M. W., Pusey, S. M., Su, F. et al., Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc. Natl. Acad. Sci. USA 2003, 100, 12343-12348.
16. Baggerly, K. A., Morris, J. S., Coombes, K. R., Reproducibility of SELDI-TOF protein patterns in serum: Comparing datasets from different experiments. Bioinformatics 2004, 20, 777-785.
17. Diamandis, E. P., Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J. Natl. Cancer. Inst. 2004, 96, 353-356.
18. Mehta, A. I., Ross, S., Lowenthal, M. S., Fusaro, V. et al., Biomarker amplification by serum carrier protein binding. Dis. Markers 2003, 19, 1-10.
19. Semmes, O. J., Feng, Z., Adam, B. L., Banez, L. L. et al., Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 2005, 51, 102-112.
20. Belluco, C., Petricoin, E. F., Mammano, E., Facchiano, F. et al., Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann. Surg. Oncol. 2007 9, 2470-2476.
21. McLerran, D., Grizzle, W. E., Feng, Z., Bigbee, W. L. et al., Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: Sources of sample bias. Clin. Chem. 2008, 54, 44-52.
22. McLerran, D., Grizzle, W. E., Feng, Z., Thompson, I. M. et al., SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem. 2008, 54, 53-60.
23. Banks, R. E., Preanalytical influences in clinical proteomic studies: Raising awareness of fundamental issues in sample banking. Clin. Chem. 2008, 54, 6-7.
24. Kohn, E. C., Azad, N., Annunziata, C., Dhamoon, A. S., Whiteley, G., Proteomics as a tool for biomarker discovery. Dis. Markers 2007, 23, 411-417.
25. Liotta, L. A., Petricoin, E. F., Putting the "bio" back into biomarkers: Orienting proteomic discovery toward biology and away from the measurement platform. Clin. Chem. 2008, 54, 3-5.
26. Hortin, G. L., Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin. Chem. 2005, 51, 3-5.
27. Shi, L., Tong, W., Fang, H., Scherf, U. et al., Cross-platform comparability of microarray technology: Intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics 2005, 6, S12.
28. Fuscoe, J. C., Tong, W., Shi, L., QA/QC issues to aid regulatory acceptance of microarray gene expression data. Environ. Mol. Mutagen. 2007, 48, 349-353.
29. Mansfield, E., O'Leary, T. J., Gutman, S. I., Food and Drug Administration regulation of in vitro diagnostic devices. J. Mol. Diagn. 2005, 7, 2-7.
30. Hackett, J. L., Gutman, S. I., Introduction to the Food and Drug Administration (FDA) regulatory process. J. Proteome Res. 2005, 4, 1110-1113.
31. Aziz, K. J., The FDA's Critical Path Initiative for Medical Products. J. Clin. Ligand Assay 2006, 29, 171-176.
32. Kling, J., Roche's microarray tests US FDA's diagnostic policy. Nat. Biotechnol. 2003, 21, 959-960.
33. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D. et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
34. Glas, A. M., Floore, A., Delahaye, L. J., Witteveen, A. T. et al., Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genom. 2006, 7, 278.
35. Marchionni, L., Wilson, R. F., Wolff, A. C., Marinopoulos, S. et al., Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann. Intern. Med. 2008, 148, 358-369.
36. Harris, L., Fritsche, H., Mennel, R., Norton, L. et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287-5312.